Cargando…
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742632/ https://www.ncbi.nlm.nih.gov/pubmed/26800078 http://dx.doi.org/10.1038/bcj.2015.115 |
_version_ | 1782414229213544448 |
---|---|
author | Gagez, A-L Tuaillon, E Cezar, R Dartigeas, C Mahé, B Letestu, R Maisonneuve, H Gouilleux-Gruart, V Bollore, K Ferrant, E Aurran, T Feugier, P Leprêtre, S Cartron, G |
author_facet | Gagez, A-L Tuaillon, E Cezar, R Dartigeas, C Mahé, B Letestu, R Maisonneuve, H Gouilleux-Gruart, V Bollore, K Ferrant, E Aurran, T Feugier, P Leprêtre, S Cartron, G |
author_sort | Gagez, A-L |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-4742632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47426322016-02-22 Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups Gagez, A-L Tuaillon, E Cezar, R Dartigeas, C Mahé, B Letestu, R Maisonneuve, H Gouilleux-Gruart, V Bollore, K Ferrant, E Aurran, T Feugier, P Leprêtre, S Cartron, G Blood Cancer J Letter to the Editor Nature Publishing Group 2016-01 2016-01-22 /pmc/articles/PMC4742632/ /pubmed/26800078 http://dx.doi.org/10.1038/bcj.2015.115 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Letter to the Editor Gagez, A-L Tuaillon, E Cezar, R Dartigeas, C Mahé, B Letestu, R Maisonneuve, H Gouilleux-Gruart, V Bollore, K Ferrant, E Aurran, T Feugier, P Leprêtre, S Cartron, G Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title_full | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title_fullStr | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title_full_unstemmed | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title_short | Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups |
title_sort | response to rituximab in b-cll patients is adversely impacted by frequency of il-10 competent b cells and fcγriiia polymorphism. a study of fcgcll/wm and goelams groups |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742632/ https://www.ncbi.nlm.nih.gov/pubmed/26800078 http://dx.doi.org/10.1038/bcj.2015.115 |
work_keys_str_mv | AT gagezal responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT tuaillone responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT cezarr responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT dartigeasc responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT maheb responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT letestur responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT maisonneuveh responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT gouilleuxgruartv responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT bollorek responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT ferrante responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT aurrant responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT feugierp responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT lepretres responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups AT cartrong responsetorituximabinbcllpatientsisadverselyimpactedbyfrequencyofil10competentbcellsandfcgriiiapolymorphismastudyoffcgcllwmandgoelamsgroups |